UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 21, 2017

 

 

ZIMMER BIOMET HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-16407   13-4151777
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

345 East Main Street

Warsaw, Indiana 46580

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (574) 267-6131

Not applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the

Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of

this chapter).

Emerging growth company    ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended

transition period for complying with any new or revised financial accounting standards provided pursuant to Section

13(a) of the Exchange Act.                  ☐

 

 

 


Item 8.01 Other Events.

On July 21, 2017, Zimmer Biomet Holdings, Inc. (the “Company”) announced that Adam R. Johnson, Group President for the Spine, Dental, Craniomaxillofacial and Thoracic business units, will resign effective September 1, 2017. Mr. Johnson informed the Company that, with the integration of LDR substantially complete and new leaders in place in Zimmer Biomet’s Spine and Dental business units, his decision was motivated by his desire to pursue his professional goals that include a career in private equity. Chris Jefferis, Vice President of Finance for Spine, Dental, Craniomaxillofacial and Thoracic, will serve as the Interim Group President until a permanent successor has been named. Mr. Jefferis will report directly to Daniel Florin, Interim Chief Executive Officer, Senior Vice President and Chief Financial Officer.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 21, 2017

 

ZIMMER BIOMET HOLDINGS, INC.
By:   /s/ Chad F. Phipps
Name:   Chad F. Phipps
Title:   Senior Vice President, General Counsel
  and Secretary